Ignite Creation Date:
2024-05-06 @ 7:52 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06163924
Status:
RECRUITING
Last Update Posted:
2024-01-23
First Post:
2023-12-01
Brief Title:
The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT
Sponsor:
Chinese University of Hong Kong
Organization:
Chinese University of Hong Kong
Study Overview
Official Title:
To Investigate the Effect of Multidisciplinary Care Approach on Cardiovascular Risk Modification in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prostate cancer is characterised by its slow progression nature and even for metastatic disease the 5-year survival is up to 30 While ADT can effectively control disease there is increasing evidence suggesting that it can also result in many adverse cardiovascular side effects on the patients and these effects are particularly important due to the prolonged survival of these patients There are suggestions that close cardiovascular CV monitoring will help to reduce cardiovascular risk and related morbidities However there is limited data to show the positive impact of these monitoring could reducing CV risk and morbidities Moreover information regarding the optimal follow-up approach and schedule is also lacking Therefore there is a need to have more information on the approach to monitoring the CV risk and the real-life impact of this monitoring on our patients Patients diagnosed with prostate cancer and plan to receive ADT are invited to participate in this study to assess the potential benefit of multidisciplinary care approach to CV risk modification
Detailed Description:
Prostate Cancer PCa and androgen deprivation therapy ADT PCa is the most common cancer and the second leading cancer death in adult male globally In Hong Kong it is one of the most rapidly increasing cancer and is now the third most common cancer and the 4th leading cancer death in male Despite the increased usage of serum PSA for early cancer diagnosis more than 50 of patients were diagnosed at stage III ampamp IV with lymph node - bone visceral metastasis Therefore ADT is still commonly used in PCa patients both as neo-adjuvant adjuvant to radiotherapyas well as backbone therapy for metastatic diseaseWhile the overall survival of PCa patients has been prolonged by ADT there is also increasing concern about potential long-term side effects in particular cardiovascular effect
Therefore there is a need for prospective studies to understand the role of close cardiovascular assessment monitoring and treatment on the cardiovascular risk of PCa patients receiving ADT Information on the risk factors at baseline follow-up and also treatment secondary prevention adopted will help to provide evidence to fill the current knowledge gap and build practical guidelines for clinical usage In the long run the data will also help to estimate the medical resources required for future health care planning to cope with the medical needs of the rapidly increasing PCa population
Therefore there is a need for prospective studies to understand the role of close cardiovascular assessment monitoring and treatment on the cardiovascular risk of PCa patients receiving ADT Information on the risk factors at baseline follow-up and also treatment secondary prevention adopted will help to provide evidence to fill the current knowledge gap and build practical guidelines for clinical usage In the long run the data will also help to estimate the medical resources required for future health care planning to cope with the medical needs of the rapidly increasing PCa population
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None